Denosumab (Prolia/Xgeva)
PeptideDenosumab is a fully human monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor-κB ligand), the key mediator of osteoclast formation and activity. FDA-approved in 2010 for osteoporosis (Prolia, 60mg every 6 months) and bone metastases (Xgeva, 120mg monthly). The landmark FREEDOM trial demonstrated significant reductions in vertebral, hip, and nonvertebral fractures, with benefits sustained up to 10 years in extension studies.
Quick Answer
What it is
Denosumab is a fully human monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor-κB ligand), the key mediator of osteoclast formation and activity. FDA-approved in 2010 for osteoporosis (Prolia, 60mg every 6 months) and bone metastases (Xgeva, 120mg monthly).
Key findings
- Grade A: Vertebral Fracture Risk (Osteoporosis)
- Grade A: Hip Fracture Risk (Osteoporosis)
- Grade A: Nonvertebral Fracture Risk (Osteoporosis)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Denosumab (Prolia/Xgeva)
Quick Facts: Denosumab (Prolia/Xgeva)
- Best Evidence:Grade A
- Conditions Studied:3
- Research Outcomes:14
- Grade A Findings:8
- Grade B Findings:3
- Key Effect:Osteoporosis
Detailed Outcomes
Evidence by Condition
Research Citations (64)
Related Peptides
Teriparatide (Forteo)
Peptide2 shared conditions · 13 outcomes
Teriparatide (brand name Forteo) is a recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). It was FDA-approved in November 2002 as the first anabolic agent for osteoporosis treatment. Unlike antiresorptive drugs, teriparatide stimulates new bone formation. It is indicated for postmenopausal women and men with osteoporosis at high fracture risk, and for glucocorticoid-induced osteoporosis.
Romosozumab (Evenity)
Peptide2 shared conditions · 11 outcomes
Romosozumab (Evenity) is a humanized monoclonal antibody that inhibits sclerostin, a key negative regulator of bone formation. FDA-approved in April 2019 for postmenopausal women with osteoporosis at high fracture risk. It has a unique dual mechanism: stimulating bone formation while reducing bone resorption. The FRAME and ARCH trials demonstrated significant reductions in vertebral and clinical fractures.
Calcitonin Salmon
Peptide2 shared conditions · 14 outcomes
Calcitonin salmon is a 32-amino acid peptide hormone analog used for postmenopausal osteoporosis and hypercalcemia. FDA-approved since 1975 as nasal spray (200 IU daily) and injection (100 IU daily). A-GRADE evidence: PROOF trial showed 33% reduction in vertebral fractures at 200 IU daily. A-GRADE for bone turnover marker reduction and acute fracture pain relief. B-GRADE for BMD increase and chronic bone pain. Has unique analgesic properties making it useful for acute osteoporotic fracture pain. Salmon calcitonin has 40-50x greater potency than human calcitonin. PRESCRIPTION ONLY - second-line osteoporosis treatment after bisphosphonates.